Chronic Obstructive Pulmonary Disease | Access and Reimbursement | US | 2016
The U.S. therapy market for chronic obstructive pulmonary disease (COPD) is becoming increasingly crowded. As more therapies with similar clinical profiles launch and the threat of generic versions of the market leaders looms, payers have become particularly sensitive to the cost of COPD drugs. What impact does this payer pressure have on the prescribing of current therapies and the market access outlook for emerging therapies?
